ArticleNeurospine2022
Glioma Immunotherapy: Advances and Challenges for Spinal Cord Gliomas.
Article in Neurospine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 26 citations in OpenAlex.
- Contrastive multimodal deep learning for survival prediction in grade 2/3 gliomas.JNCI cancer spectrum · 2026Article
- Decoding the Sphingolipid Landscape of Clear Cell Renal Cell Carcinoma: A Single-Cell-Guided Prognostic Model Built With 101 Machine Learning.Human mutation · 2026Article
- Tips and tricks of spinal cord biopsy: insights from a multicenter series of 61 patients.Journal of neuro-oncology · 2025Article
- The impact of adjuvant radiotherapy on overall survival in spinal low-grade gliomas: a propensity score-matched analysis.Journal of neuro-oncology · 2025Article
- Article
- Improving glioma drug delivery: A multifaceted approach for glioma drug development.Pharmacological research · 2024Review
- Review
- A Nomogram for Predicting Overall Survival of Patients With Primary Spinal Cord Glioblastoma.Neurospine · 2024Article
- A comprehensive neuroimaging review of the primary and metastatic brain tumors treated with immunotherapy: current status, and the application of advanced imaging approaches and artificial intelligence.Frontiers in immunology · 2024Review
- The evolution of spinal cord surgery: history, people, instruments, and results.Child's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery · 2023Review
- Neurological Outcome and Respiratory Insufficiency in Intramedullary Tumors of the Upper Cervical Spine.Medicina (Kaunas, Lithuania) · 2023Article
- Clinical Characteristics and Treatment Outcomes of Long-Level Intramedullary Spinal Cord Tumors: A Consecutive Series of 43 Cases.Neurospine · 2023Article
- Title: Immunotherapy; a ground-breaking remedy for spinal cord injury with stumbling blocks: An overview.Frontiers in pharmacology · 2023Review
- Current and Emerging Approaches for Spine Tumor Treatment.International journal of molecular sciences · 2022Review
- Article
- Atypical imaging features of the primary spinal cord glioblastoma: A case report.World journal of clinical cases · 2022Article
- Another Milestone for Spinal Intramedullary Tumor Treatment.Neurospine · 2022Article
- Delivering Glioblastoma a Kick-DGKα Inhibition as a Promising Therapeutic Strategy for GBM.Cancers · 2022Review
- The inhibitory effect of human umbilical cord mesenchymal stem cells expressing anti-HAAH scFv-sTRAIL fusion protein on glioma.Frontiers in bioengineering and biotechnology · 2022Article
- Cuproptosis key gene FDX1 is a prognostic biomarker and associated with immune infiltration in glioma.Frontiers in medicine · 2022Article
Corrections and comments
- Commented on by
Authors and funding
7 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Spinal cord gliomas are rare entities that often have limited surgical options. Immunotherapy has shown promise in intracranial gliomas with some research suggesting benefit for spinal cord gliomas. A focused review of immunotherapies that have been investigated in spinal cord gliomas was performed. The primary methods of immunotherapy investigated in spinal cord gliomas include immune checkpoint inhibitors, adoptive T-cell therapies, and vaccine strategies. There are innumerable challenges that must be overcome to effectively apply immunotherapeutic strategies to the spinal cord gliomas including low incidence, few antigenic targets, the blood spinal cord barrier, the immunosuppressive tumor microenvironment and neurotoxic treatment effects. Nonetheless, research has suggested ways to overcome these challenges and treatments have been effective in case reports for metastatic non-small cell lung cancer, melanoma, midline glioma and glioblastoma. Current therapies for spinal cord gliomas are markedly limited. Further research is needed to determine if the success of immunotherapy for intracranial gliomas can be effectively applied to these unique tumors.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.